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Abstract
Background: Single nucleotide polymorphisms (SNPs) within the gene encoding Hexokinase 1 (HK1) are associated
with changes in glycated haemoglobin (HbA1c) levels. Our aim was to investigate the effect of HK1 rs7072268 on
measures of glucose- and lipid-metabolism in a Danish non-diabetic population and combine the outcome of
these analyses in a meta-analysis with previously published results. Furthermore, our aim was to perform a type 2
diabetes case-control analysis and meta-analysis with two previous case-control studies.
Methods: SNP rs7072268 was genotyped in 9,724 Danes. The quantitative trait study included 5,604 non-diabetic
individuals from the Inter99 cohort. The case-control study included 4,449 glucose tolerant individuals and 3,398
patients with type 2 diabetes. Meta-analyses on quantitative traits included 24,560 Caucasian individuals and 30,802
individuals were included in the combined analysis of present and previous type 2 diabetes case-control studies.
Results: Using an additive model, we confirmed that the T-allele of rs7072268 associates with increased HbA1c of
0.6% (CI: 0.4 - 0.9), p = 3*10-7 per allele. The same allele associated with an increased area under the curve (AUC)
for glucose of 5.0 mmol/l*min (0.1 - 10.0), p = 0.045 following an oral glucose tolerance test (OGTT) and increased
fasting levels of cholesterol of 0.06 mmol/l (0.03 - 1.0), p = 0.001 and triglycerides of 2.0% (0.2 - 3.8), p = 0.03 per
allele in the same study sample of non-diabetic individuals from the Inter99 cohort. However, the T-allele did not
show any association with estimates of insulin release or insulin sensitivity neither in Inter99 nor in combined
analyses. The prevalence of type 2 diabetes was increased among carriers of the rs7072268 T-allele both in the
Danish study-population with an OR of 1.11 (1.02-1.21) and in a meta-analysis including the two additional sample
sets with an OR of 1.06 (1.02-1.11). However, after Bonferroni correction the T-allele only remained associated to
HbA1c and fasting cholesterol.
Conclusions: The present study provides suggestive evidence of an association of the rs7072268 T-allele in HK1
with increased AUC glucose following an OGTT in non-diabetic individuals and a nominal association with type 2
diabetes prior to Bonferroni correction. The latter was confirmed in combined analyses involving 16,445 cases and
14,357 control subjects.
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Background
The T-allele of rs7072268, located in intron 7 of the
gene encoding the hexokinase 1 (HK1), has previously
been associated with higher glycated haemoglobin levels
(HbA1c) in a genome-wide association study (GWAS)
among more than 14,000 women [1]. These findings
were confirmed in another study showing an association
between the same SNP allele and increased HbA1c
levels [2]. A different common variant located in HK1
(rs16926246) has also been identified in a GWAS as a
variant associating with increased HbA1c levels [3]. Yet,
rs7072268 was further investigated for association with
glucose homeostasis-related traits such as fasting glu-
cose, fasting insulin, HOMA-B (Homeostatic model
assessment of b-cell function) and HOMA-IR (Homeo-
static model assessment of insulin resistance) but no sig-
nificant effects were found [2]. However, it has been
shown that rs7072268 associates with red blood cells -
variables, e.g. red blood cell count, hematocrit, and ane-
mia and not to type 2 diabetes (T2DM) related traits [2].
HK1 is expressed in all mammalian tissues, and is
considered a “housekeeping enzyme” [4]. HK1 is respon-
sible for the first step in glucose utilization and it has
been hypothesized that HK1 variants may affect glucose
metabolism and thereby risk of T2DM [1]. Thus, the
aim of present study was to validate the previously
observed outcome of the rs7072268 within HK1 on 1)
quantitative metabolic traits in a random sample of
5,604 adult Danish non-diabetic individuals with avail-
able data on glucose homeostasis and lipid variables and
2) on prevalence of T2DM in a case-control study
including 4,449 glucose tolerant individuals and 3,398
patients with T2DM. Furthermore, we combined the
outcomes of the present analyses with previously pub-
lished results in a meta-analysis.
Methods
Danish study populations
Individuals included in the present study were ascer-
tained from three study populations: 1) 6,282 individuals
were included from a population-based, randomized,
non-pharmacological intervention study for the preven-
tion of ischemic heart disease including middle-aged
individuals; Inter99 (http://ClinicalTrials.gov identifica-
tion no. NCT00289237) [5]. 2) 1,621 individuals from a
population-based, high-risk screening and intervention
study for T2DM in general practice; ADDITION
(Anglo-Danish-Dutch Study of Intensive Treatment in
People with Screen-Detected Diabetes in Primary Care)
(http://ClinicalTrials.gov ID-no: NCT00237548) [6]. 3)
1,439 individuals from a sample of unrelated type 2 dia-
betic patients sampled through the out-patient clinic at
Steno Diabetes Center; SDC. Among Inter99 partici-
pants glucose tolerance status was defined according to
WHO 1999 criteria [7] and in the present quantitative
trait study we included only non-diabetic individuals
from Inter99.
The case-control study included 4,449 glucose tolerant
individuals and 3,398 patients with T2DM. For further
description see Table 1. Patients having diabetes as a
consequence of known chronic pancreatitis, haemochro-
matosis, mutations in the insulin receptor, lipodystrophy,
maturity-onset diabetes of the young, maternally inher-
ited diabetes and deafness, family history of first-degree
relatives with Type 1 diabetes, insulin requirement within
the first year after diabetes diagnosis or a fasting serum
C-peptide level ≤ 150 pmol/l at time of recruitment were
excluded from the category of clinically defined T2DM.
All participants were Danish Caucasians by self-report,
and informed written consent was obtained from all
subjects before participation. The studies were approved
by the Ethical Committees of Copenhagen and Aarhus,
and were in accordance with the principles of the Hel-
sinki Declaration II.
Study samples included in the combined analyses
Details of the French study populations included in the
meta-analyses are reported by Bonnefond and colleagues
[2]. In short, five Caucasian study populations including
a total of 18,956 non-diabetic individuals were included
in the study. This study also included a case-control
study conducted among 7,447 patients with T2DM and
5,380 normoglycemic participants [2].
Participants from the Diabetes Genetics Replication And
Meta-analysis (DIAGRAM) case-control study included
4,549 type 2 diabetic patients and 5,579 control individuals.
These individuals were collected from three previous
T2DM GWAS. Participants were of Caucasian descent
and are further described by Zeggini and colleagues [8].
Anthropometrics and biochemical assays
Height and weight were measured in light indoor
clothes and without shoes, and BMI was calculated as
Table 1 Description of study samples included in the
case-control study
Trait Inter99: Inter99: Addition: SDC:
Glucose tolerance
status
NGT T2DM T2DM T2DM
N (men/women) 4449
(2062/
2379)
343
(197/
126)
1613
(918/695)
1439 (902/
537)
Mean age (years) 45.2 ± 7.8 51.6 ±
7.9
60.3 ± 6.8 63.1 ± 11.0
Mean BMI (kg/m2) 25.5 ± 4.1 30.3 ±
5.8
31.1 ± 5.4 30.5 ± 5.6
Data are presented as mean ± SD. NGT, normal glucose tolerance; T2DM,
Type 2 diabetes patients.
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weight (kg)/height (m)2. Waist circumference at the
umbilical level was measured on subjects in an upright
position to the nearest 0.5 cm using a non-extendable
linen tape measure according to WHO recommendation.
Blood samples were drawn after a 12-h overnight fast.
Plasma glucose was in the Danish study par-ticipants
analysed by a glucose oxidase method (Granutest, Merck,
Darmstadt, Germany), and serum insulin (excluding des
(31,32) and intact proinsulin) was measured using the
AutoDELFIA insulin kit (Perkin-Elmer, Wallac, Turku,
Finland). Serum triglycerides and total and HDL-serum
cholesterol were analysed using enzymatic colorimetric
methods (GPO-PAP and CHOD-PAP, Roche Molecular
Biochemicals, Germany). HbA1C was measured using
ion-exchange high performance liquid chromatography
(normal reference range: 4.1-6.4%).
Genotyping
Genotyping of the HK1 rs7072268 was in the Danish
study sample performed using a Sequenom iPlex assay
[9]. The genotyping success rate was 98% and the error
rate was 0% in 203 duplicate samples. All groups of gen-
otypes obeyed Hardy-Weinberg equilibrium.
Statistical analysis
Quantitative trait analysis was performed in the Inter99
study population and did not include patients with
screen-detected or known diabetes. A general linear
model was used to test quantitative variables (or trans-
formed variables) for differences between genotype
groups. Genotype and sex were considered as fixed fac-
tors and age and BMI as covariates. Traits not following
a normal distribution were log-transformed prior to ana-
lysis. To examine genotype distribution differences
between affected and unaffected subjects logistic regres-
sion analysis was applied including adjustment for sex,
age and BMI. Individuals with unknown diabetes status
were excluded from case-control analyses for T2DM.
The meta-analyses were performed using effect size esti-
mates and SE derived from a linear regression analysis
for quantitative traits and OR with CI for case-control
studies. The effects for quantitative traits were based on
log transformed traits except for values of glucose. In
the meta-analyses both fixed effect (weight of studies
estimated using inverse variance) and random effect
(weight of studies estimated using DerSimonian-Laird
method) [10] were applied. All studies were adjusted for
age, sex and BMI. All analyses were performed using
RGui version 2.7.0. A two-sided p-value of less than
0.05 was considered to be significant.
Indices
Insulinogenic index: ((serum insulin 30 min - fasting
serum insulin))/(fasting plasma glucose)
HOMA-B: (20 * fasting serum insulin)/(fasting plasma
glucose - 3.5)
HOMA-IR: (fasting plasma glucose * fasting serum
insulin)/22.5
ISI: 10000/√(((fasting plasma glucose (mmpl/l) * 18) *
(fasting serum insulin (pmol/l)/6) * (mean glucose
(mmol/l) * 18) * (mean insulin (pmol/l)/6)))
Disposition index: ISI * Insulinogenic index
Results
Using an additive model adjusted for age, sex and BMI,
the impact of the T-allele of rs7072268 in HK1 on quanti-
tative metabolic variables was investigated in non-diabetic
adults from the Inter99 cohort. The T-allele associated
with an increase in HbA1c of 0.6% per allele (0.4 - 0.9); p
= 3 × 10-7, an increase of 5.0 mmol/l×min per allele (0.1 -
10.0); p = 0.045 for AUC for glucose under an OGTT, an
increase of 0.06 mmol/l per allele (0.03 - 1.0); p = 0.001 in
fasting total plasma cholesterol, and an increase of 2.0%
per allele (0.2 - 3.8); p = 0.03 in fasting plasma triglycerides
(Table 2). However, only associations with HbA1c and
total plasma cholesterol remained significant following
Bonferroni correction for multiple testing (Table 2).
To increase the statistical power of the study, we per-
formed a meta-analysis including quantitative metabolic
traits data from a previously published French study
including 18,956 Caucasian participants [2]. The traits
investigated in this study included the following: fasting
plasma glucose, fasting serum insulin, HOMA-B,
HOMA-IR, plasma glucose 30 min post-OGTT, plasma
glucose 120 min post-OGTT, serum insulin 30 min
post-OGTT, serum insulin 120 min post-OGTT, insuli-
nogenic index, diposition index, index of insulin sensi-
tivity and AUC for glucose. None of these combined
analyses revealed any significant effect of the HK1 var-
iant on traits related to glucose homeostasis (Figure 1
and Additional file 1, Figure S1).
In a case-control setting we examined the impact of
rs7072268 of HK1 on prevalence of T2DM. Logistic
regression analysis revealed an association between the
T-allele of rs7072268 and T2DM among 4,449 glucose
tolerant individuals and 3,389 T2DM patients with an
OR of 1.11 (1.02-1.21), p = 0.02 (Table 3). The outcome
of the Danish case-control study was included in a meta-
analysis involving 7,447 French T2DM cases and 5,380
French control subjects [2] as well as 4,549 T2DM cases
and 5,579 control subjects from the DIAGRAM consor-
tium [8]. This meta-analyses also found a significant
association between the T-allele of rs7072268 and T2DM
with an OR of 1.064 (1.021-1.11), p = 0.003 (Figure 2).
Discussion
In line with a previous study, we found that the T-allele
of rs7072268 in HK1 was associated with an increased
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concentration of HbA1c in a Danish non-diabetic popu-
lation. This effect of rs7072268 is comparable to the
results obtained from another independent variant
located in HK1 (rs16926246) which also associated with
measures of HbA1c when analysing 46,368 nondiabetic
European individuals [3]. These two variants are in low
linkage disequilibrium (r2 = 0.1). We also found an
increased level of AUC for glucose following oral glu-
cose ingestion and increased measures of fasting circu-
lating levels of triglyceride and total cholesterol.
However, the remaining traits related to glucose
homeostasis following oral glucose ingestion failed to
reveal any association with the rs7072268 variant in
HK1. A French study also failed to identify any signifi-
cant associations between the rs7072268 and glucose
regulation-related traits. We investigated these previous
traits further in a meta-analysis including a total of
24,560 individuals; yet, no significant associations were
found. However, lipid-related measures were not among
the previously examined traits and the significant asso-
ciations found in the Danish study could therefore not
be further validated in a meta-analysis. HK1 was not
Table 2 Quantitative trait analyses of the effect of rs7072268 of HK1 among 5,604 non-diabetic individuals from the
Inter99 study population
Trait CC CT TT Padd Badd (CI)
N (men/women) 1545 (765/780) 2757 (1347/1410) 1302 (644/658)
Age (years) 46.1 ± 8.0 45.8 ± 7.9 45.9 ± 7.7
Body composition
BMI (kg/m2) 25.9 ± 4.4 26.1 ± 4.4 26.0 ± 4.3 0.5 0.06 (-0.10; 0.22)
Waist-to-hip ratio 0.85 ± 0.08 0.85 ± 0.09 0.85 ± 0.09 0.2 0.001 (-0.001; 0.003)
Waist (cm) 86.7 ± 12.9 86.1 ± 12.8 85.8 ± 12.8 0.9 -0.12 (-0.20; 0.18)
Lipids
Triglycerides* (mmol/l) 1.0 (0.8; 1.4) 1.1 (0.8; 1.5) 1.1 (0.8; 1.5) 0.03 2.0 (0.2;3.8)
Cholesterol (mmol/l) 5.5 ± 1.0 5.5 ± 1.1 5.6 ± 1.1 0.001 0.06 (0.03; 1.0)
HDL cholesterol (mmol/l) 1.4 ± 0.4 1.4 ± 0.4 1.4 ± 0.4 0.7 0.003 (-0.010; 0.016)
LDL cholesterol (mmol/l) 3.5 ± 1.0 3.5 ± 0.9 3.6 ± 1.0 0.1 0.04 (-0.01; 0.09)
VLDL cholesterol (mmol/l) 0.6 ± 0.3 0.6 ± 0.3 0.6 ± 0.3 0.1 0.01 (-0.004; 0.03)
Serum Insulin
Fasting serum Insulin *
(pmol/l)
33.0 (23.0; 47.0) 34.0 (24.0; 51.0) 33.0 (23.0; 51.0) 0.2 1.2 (-0.7; 2.7)
Serum insulin 30 min *
(pmol/l)
242 (173; 355) 250 (179; 354) 244 (179; 359) 0.6 0.5 (-1.4; 2.4)
Serum insulin 120 min * (pmol/l) 151 (94.3; 242) 155 (96.0; 249) 148 (91.0; 248) 0.9 0.1 (-2.6; 2.9)
AUC insulin*
(pmol/l * min)
22460 (16200; 32620) 23490 (16950; 32770) 22820 (16770; 32910) 0.2 0.8 (-1.1; 2.6)
Plasma glucose
Fasting Plasma glucose (mmol/l) 5.4 ± 0.5 5.5 ± 0.5 5.5 ± 0.5 0.2 0.01 (-0.004; 0.03)
Plasma glucose 30 min (mmol/l) 8.5 ± 1.67 8.6 ± 1.7 8.6 ± 1.7 0.1 0.05 (-0.004; 0.1)
Plasma glucose 120 min (mmol/l) 5.9 ± 1.56 6.0 ± 1.5 6.0 ± 1.5 0.1 0.04 (-0.02; 0.09)
AUC glucose
(mmol/l* min)
856 ± 143 865 ± 145 866 ± 144 0.045 5.0 (0.1; 10.0)
Indices of insulin sensitivity
HOMA-IR* 7.8 (5.4; 11.6) 8.3 (5.7; 12.6) 7.9 (5.4; 12.8) 0.2 1.3 (-0.6; 3.3)
DI* 204 (140; 291) 194 (130; 279) 197 (129; 285) 0.3 -1.2 (-3.3; 0.9)
ISI* 8.3 (5.6; 9.5) 7.8 (5.3; 11.1) 8.0 (5.2; 11.6) 0.1 -1.4 (-3.2-0.4)
Indices of acute insulin response
Insulinolinogenic Index* 24.9 (17.3; 37.1) 25.1 (17.0; 37.3) 24.7 (17.4; 36.1) 0.8 0.4 (-1.8; 2.5)
Glycated haemoglobin levels
Hba1c* (%) 5.8 (5.5; 6.0) 5.8 (5.5; 6.1) 5.8 (5.6; 6.1) 3e-07 0.6 (0.4; 0.9)
Data are presented as mean ± SD and as effect sizes (95% CI) for traits following a normal distribution. Remaining traits are presented as median (inter-quartile
range) and their effect sizes are presented as increase/decrease in percentage. Multiple regression analysis was used to test for difference between genotype
groups. P-values are corrected for sex and age. * = log transformation.
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Figure 1 Meta-analyses estimating the combined effect and 95% confidence interval of the T-allele of rs7072268 in HK1 from the
present study and the study by Bonnefond et al. [2]on quantitative metabolic traits. Estimates for fasting insulin, HOMA-IR, HOMA-B,
Insulinogenic index and disposition index are based on log transformed traits. The black diamonds represent the combined effects of the studies
weight using inverse variance. The grey diamonds represent the combined effects of the studies which were weighted using the DerSimonian-
Laird method.
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identified as a locus associating with fasting glucose,
fasting insulin, HOMA-B and HOMA-IR in a meta-ana-
lysis of 21 GWAS [11].
Another significant finding was the association
between the T-allele of rs7072268 and T2DM. This
finding was further supported by a meta-analysis
combining the effect of the rs7072268 variant in this
study with two additional studies [2,8]. This effect was
not significant after Bonferroni correction. However,
Bonferroni correction is a very conservative method
assuming independence between traits which is not a
correct assumption for the included traits and validation
Table 3 Estimation of the effect of rs7072268 of HK1 on the risk of T2DM in a case-control study among 9,724 Danes
NGT T2DM OR (95% CI) 1 OR (95% CI) 2 P1 P2
CC (%) 1244(28) 938(27.7)
CT (%) 2182 (49) 1686 (49.7)
TT (%) 1023 (23) 765 (22.6)
MAF (95% CI) 47.5 (46.5-48.6) 47.4 (46.3-48.6) 1.11 (1.02-1.21) 1.12 (1.02-1.24) 0.02 0.02
OR (95% CI) 1; Odd ratio adjusted sex and age. OR (95% CI) 2; Odd ratio adjusted sex, age and BMI. P-values are calculated using logistic regression. P1; Adjusted
for sex and age. P2; Adjusted for sex, age and BMI. T2DM; Type 2 diabetes, NGT; Normal glucose tolerance.
 
 
 
Figure 2 Meta-analyses estimating the combined effect and 95% confidence interval of the T-allele of rs7072268 in HK1 from the
present study, the study by Bonnefond et al. [2] and the DIAGRAM study [8] on risk of type 2 diabetes. The black diamonds represent
the combined effects of the studies weight using inverse variance. The grey diamonds represent the combined effects of the studies which
were weighted using the DerSimonian-Laird method.
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of the present result in an independent study sample is
crucial. However, the largest type 2 diabetes GWAS
conducted to date failed to identify a genome-wide sig-
nificant effect of this variant [12]. Nevertheless, the high
threshold of significance for GWAS may cause true
associations having only minor effects to be hidden in
the fog of random associations and the effect of
rs7072268 on type 2 diabetes observed in present study
may not be a result of a type 1 error.
Biologically, hexokinase 1 is one of the key enzymes of
glycolysis and catalyzes the phosphorylation of glucose
to glucose-6-phosphate on the mitochondria. HK1 is
found in all mammalian tissues; yet, the only tissues
depending solely on HK1 for glucose utilisation are tis-
sues having a strict dependence on glucose utilization
for their physiologic functions, such as brain, erythro-
cytes, platelets, lymphocytes, and fibroblasts [13-15]. A
minor defect in HK1 may therefore mainly be apparent
intracellular in such tissue without causing measureable
physiological changes such as circulating plasma glu-
cose, as the majority of tissue is relaying on several hex-
okinases, possibly compensating for such a minor defect.
Therefore, despite the lack of significant effects on mea-
sures of circulating glucose, rs7072268 may have an
effect on intracellular glycemic metabolism, which is
possibly causing the association with increased HbA1c.
There is no direct biological link between the function
of HK1 and circulating cholesterol levels and the
observed association may despite Bonferroni correction
be a type 1 error thus replication of this finding is
essential. However, the association with increased levels
of fasting lipids observed in non-diabetic individuals
may be an early metabolic consequence of this variant
related to a slightly altered glucose metabolism, as it is
well known that adverse changes in lipids - such as
increased triglyceride and cholesterol levels - are seen in
pre-diabetic and/or metabolic syndrome individuals long
before the onset of T2DM [16]. Therefore, it is plausible
that rs7072268 or a functional variant within close
proximity has an effect on intracellular glucose utilisa-
tion which may indirectly affect lipid metabolism.
A monogenic form of HK1 deficiency has been
described and the primary effect of this deficiency was
hemolytic anemia, however, there were no information
regarding the glycemic control of these patients [17].
Also, rs7072268 has previously been associated with a
pro-anemic state [2]. However, whether there is a con-
nection between glucose-metabolism and anemia is not
well established. It has recently been found that the fre-
quency of anemia was increased in diabetic patients [18]
and it was seen in a Chinese population that anaemia
was associated with an increased risk of hyperglycaemia
[19]. Thus, it is possible that HK1 may be a factor influ-
encing both maintenance of the red blood cells pool
and glucose-homeostasis and may even be a link
between them.
Despite the large number of individuals included, the
present may be underpowered as the effects of the
rs7072268 on measure of glucose homeostasis are
minor, thus requiring a large number of participants.
Conclusion
Based on the present results, we suggest that the T-
allele of rs7072268 in HK1 associates with T2DM as
well as fasting dyslipidaemia in non-diabetic individuals
prior to Bonferroni correction.
Additional material
Additional file 1: Figure S1. Meta-analyses estimating the combined
effect and 95% confidence interval of the T-allele of rs7072268 in HK1
from from the present study and the study by Bonnefond and co-
workers [2] on plasma glucose 30 and 120 minutes after an OGTT, serum
insulin 30 and 120 minutes after an OGTT and insulin sensitivity index
(ISI). Below Figure S1: Estimates for insulin and insulin sensitivity index
(ISI) are based on log transformed traits. The black diamonds represent
the combined effects of the studies weight using inverse variance. The
grey diamonds represent the combined effects of the studies which
were weighted using the DerSimonian-Laird method.
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AUC: Area Under the Curve; GWAS: Genome Wide Association Study; HbA1c:
Glycated Haemoglobin 1c; HK: Hexokinase; ISI: Insulin Sensitivity Index; SNP:
Single Nucleotide Polymorphism; T2DM: Type 2 Diabetes.
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